BioCentury
ARTICLE | Politics, Policy & Law

IPR battles

Who's winning and who's losing at IPR so far

September 14, 2015 7:00 AM UTC

A bipartisan backlash against the pricing of specialty drugs has eroded the biopharma industry's political support, leading members of Congress to question whether efforts to exempt drug patents from the inter partes review system would protect innovation or simply prop up profits.

While BIO and PhRMA may achieve an IPR carve-out, recent decisions by the U.S. Patent and Trademark Office suggest that retention of the IPR process would not be an unmitigated disaster for biopharma innovators. ...